{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T20:02:37Z","timestamp":1792526557115,"version":"4.5.0"},"reference-count":59,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Microorganisms"],"abstract":"<jats:p>Viral conjunctivitis is a highly contagious ocular condition that significantly impacts patient quality of life and healthcare resources. Despite its self-limiting nature, the condition remains a significant public health concern due to its high transmissibility, prolonged symptoms, and potential complications such as subepithelial infiltrates (SEIs). This review aimed to synthesize and evaluate current management strategies for adenoviral conjunctivitis and provide an evidence-based treatment framework. A systematic literature search of PubMed and the Cochrane Library was conducted, identifying 25 eligible studies published between 2009 and 2024 that focused on clinical interventions including supportive care, antiseptics, corticosteroids, antivirals, and immune modulators. The findings indicate that while supportive therapy and hygiene measures remain central to care, antiseptic agents, specifically povidone\u2013iodine, and topical steroids offer additional benefit in reducing symptom duration and complications. Combination therapies integrating antiseptics, corticosteroids, and immunomodulators show promise for more severe cases, especially those complicated by SEIs. This review proposes an evidence-based comprehensive, multimodal approach management algorithm while highlighting the need for future research in antiviral development and diagnostic innovation to avoid mistreatment and unnecessary antibiotic use.<\/jats:p>","DOI":"10.3390\/microorganisms13081712","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T11:44:45Z","timestamp":1753184685000},"page":"1712","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["An Update on Viral Conjunctivitis Treatment Strategies: A Narrative Literature Review"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2625-5656","authenticated-orcid":false,"given":"Maheshver","family":"Shunmugam","sequence":"first","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, University of British Columbia, 2550 Willow Street, Vancouver, BC V5Z 3N9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7661-6675","authenticated-orcid":false,"given":"Francesca","family":"Giovannetti","sequence":"additional","affiliation":[{"name":"Department of Sense Organs, Sapienza University of Rome, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1197-8026","authenticated-orcid":false,"given":"Sonia N.","family":"Yeung","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, University of British Columbia, 2550 Willow Street, Vancouver, BC V5Z 3N9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Iovieno","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, University of British Columbia, 2550 Willow Street, Vancouver, BC V5Z 3N9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,22]]},"reference":[{"key":"ref_1","unstructured":"Hashmi, M.F., Gurnani, B., and Benson, S. (2025, January 10). Conjunctivitis, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK541034\/."},{"key":"ref_2","unstructured":"Baab, S., Le, P.H., Gurnani, B., and Kinzer, E.E. (2025, June 28). Allergic Conjunctivitis, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK448118\/."},{"key":"ref_3","unstructured":"Hamrah, P. (2025, June 29). Toxic Conjunctivitis. Available online: https:\/\/www.uptodate.com\/contents\/toxic-conjunctivitis#references."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.4103\/ijo.IJO_604_20","article-title":"Chronic cicatrizing conjunctivitis: A review of the differential diagnosis and an algorithmic approach to management","volume":"68","author":"Vazirani","year":"2020","journal-title":"Indian J. Ophthalmol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1185\/03007990903038269","article-title":"Acute conjunctivitis: Truth and misconceptions","volume":"25","author":"Jeng","year":"2009","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"341","DOI":"10.3109\/09273948.2010.498658","article-title":"Cellular and tissue architecture of conjunctival membranes in epidemic keratoconjunctivitis","volume":"18","author":"Chintakuntlawar","year":"2010","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"837","DOI":"10.2147\/OPTH.S207976","article-title":"Management of Adenoviral Keratoconjunctivitis: Challenges and Solutions","volume":"14","author":"Labib","year":"2020","journal-title":"Clin. Ophthalmol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/ICU.0b013e3283477cb5","article-title":"Adenovirus advances: New diagnostic and therapeutic options","volume":"22","author":"Kaufman","year":"2011","journal-title":"Curr. Opin. Ophthalmol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"101873","DOI":"10.1016\/j.clae.2023.101873","article-title":"A systematic review and meta-analysis on the efficacy of topical povidone iodine in adenoviral conjunctivitis","volume":"46","year":"2023","journal-title":"Cont. Lens Anterior Eye"},{"key":"ref_10","unstructured":"Solano, D.F.L., and Czyz, C.N. (2025, February 12). Viral Conjunctivitis, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK470271\/."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1056\/NEJMra2216081","article-title":"Eye infections","volume":"389","author":"Durand","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1001\/jama.2022.7687","article-title":"Does This Patient With Acute Infectious Conjunctivitis Have a Bacterial Infection?: The Rational Clinical Examination Systematic Review","volume":"327","author":"Johnson","year":"2022","journal-title":"JAMA"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1136\/bmj.38128.631319.AE","article-title":"Predicting bacterial cause in infectious conjunctivitis: Cohort study on informativeness of combinations of signs and symptoms","volume":"329","author":"Rietveld","year":"2004","journal-title":"BMJ"},{"key":"ref_14","unstructured":"Pippin, M.M., and Le, J.K. (2025, March 22). Bacterial Conjunctivitis, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK546683\/."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/MAJ.0b013e3181637417","article-title":"Cost Effectiveness of a Point-of-Care Test for Adenoviral Conjunctivitis","volume":"336","author":"Udeh","year":"2008","journal-title":"AJMS"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.ophtha.2017.04.034","article-title":"Antibiotic Prescription Fills for Acute Conjunctivitis among Enrollees in a Large United States Managed Care Network","volume":"124","author":"Shekhawat","year":"2017","journal-title":"Ophthalmology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"372","DOI":"10.18502\/jovr.v15i3.7456","article-title":"Conjunctivitis: A Systematic Review","volume":"15","author":"Azari","year":"2020","journal-title":"J. Ophthalmic Vis. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jcjo.2017.12.004","article-title":"Role of the Adenoplus test in refractory, recurrent and clinically undiagnosed conjunctivitis","volume":"53","author":"Sachdev","year":"2018","journal-title":"Can. J. Ophthalmol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S1473-3099(04)01044-8","article-title":"PCR-based diagnostics for infectious diseases uses, limitations, and future applications in acute-care settings","volume":"4","author":"Yang","year":"2004","journal-title":"Lancet Infect. Dis."},{"key":"ref_20","unstructured":"Haddaway, N.R., Page, M.J., Pritchard, C.C., and McGuinness, L.A. (2025, July 02). PRISMA2020: An R package and Shiny App for Producing PRISMA 2020-Compliant Flow Diagrams, with Interactivity for Optimized Digital Transparency and Open Synthesis. Available online: https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cl2.1230."},{"key":"ref_21","first-page":"3","article-title":"Topical pharmacologic interventions versus placebo for epidemic keratoconjunctivitis","volume":"3","author":"Liu","year":"2022","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ajo.2021.05.018","article-title":"Efficacy of a Single Administration of 5% Povidone-Iodine in the Treatment of Adenoviral Conjunctivitis","volume":"231","author":"Than","year":"2021","journal-title":"Am. J. Ophthalmol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1080\/09286586.2021.1971262","article-title":"A Systematic Review of Clinical Practice Guidelines for Infectious and Non-infectious Conjunctivitis","volume":"29","author":"Chan","year":"2022","journal-title":"Ophthalmic Epidemiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.survophthal.2023.11.002","article-title":"In praise of povidone-iodine application in ophthalmology","volume":"69","author":"Soleimani","year":"2024","journal-title":"Surv. Ophthalmol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.survophthal.2015.04.001","article-title":"Adenoviral keratoconjunctivitis","volume":"60","author":"Jhanji","year":"2015","journal-title":"Surv. Ophthalmol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1089\/jop.2018.0122","article-title":"The In Vitro Evaluation of Povidone-Iodine Against Multiple Ocular Adenoviral Types","volume":"35","author":"Yates","year":"2019","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1111\/aos.16684","article-title":"Effect of chlorhexidine, povidone-iodine and betadine antiseptic eye drops on cultured human conjunctival goblet cell survival","volume":"102","author":"Hadad","year":"2024","journal-title":"Acta Ophthalmol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.jtos.2019.08.005","article-title":"Safety and tolerability of a one-time, in-office administration of 5% povidone-iodine in the treatment of adenoviral conjunctivitis: The Reducing Adenoviral Patient Infected Days (RAPID) study","volume":"17","author":"Shorter","year":"2019","journal-title":"Ocul. Surf."},{"key":"ref_29","first-page":"268","article-title":"One-time low concentration betadine eye wash: A novel treatment for epidemic viral conjunctivitis for accelerated recovery","volume":"68","author":"Vats","year":"2024","journal-title":"Rom. J. Ophthalmol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3109\/15569527.2014.888077","article-title":"Povidone iodine in the treatment of adenoviral conjunctivitis in infants","volume":"34","author":"Zihal","year":"2015","journal-title":"Cutan. Ocul. Toxicol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1080\/09273948.2020.1766510","article-title":"The Treatment Models for Adenoviral Keratoconjunctivitis in the Childhood Population","volume":"29","author":"Bekmez","year":"2021","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_32","first-page":"968","article-title":"The effects of povidone iodine (pH 4.2) on patients with adenoviral conjunctivitis","volume":"66","author":"Yazar","year":"2016","journal-title":"J. Pak. Med. Assoc."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.18240\/ijo.2019.09.08","article-title":"Effect of diluted povidone iodine in adenoviral keratoconjunctivitis on the rate of subepithelial corneal infiltrates","volume":"12","author":"Canan","year":"2019","journal-title":"Int. J. Ophthalmol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1089\/jop.2011.0082","article-title":"Treatment of epidemic keratoconjunctivitis with 2% povidone-iodine: A pilot study","volume":"28","author":"Trinavarat","year":"2012","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1167\/iovs.10-5944","article-title":"Clinical and antiviral efficacy of an ophthalmic formulation of dexamethasone povidone-iodine in a rabbit model of adenoviral keratoconjunctivitis","volume":"52","author":"Clement","year":"2011","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1007\/s12325-009-0062-1","article-title":"A combination povidone-iodine 0.4%\/dexamethasone 0.1% ophthalmic suspension in the treatment of adenoviral conjunctivitis","volume":"26","author":"Pelletier","year":"2009","journal-title":"Adv. Ther."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ajo.2018.05.012","article-title":"Randomized, Controlled, Phase 2 Trial of Povidone-Iodine\/Dexamethasone Ophthalmic Suspension for Treatment of Adenoviral Conjunctivitis","volume":"194","author":"Pepose","year":"2018","journal-title":"Am. J. Ophthalmol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"870","DOI":"10.3109\/02713683.2014.964419","article-title":"Dexamethasone\/Povidone Eye Drops versus Artificial Tears for Treatment of Presumed Viral Conjunctivitis: A Randomized Clinical Trial","volume":"40","author":"Pinto","year":"2015","journal-title":"Curr. Eye Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/aos.15689","article-title":"Efficacy of povidone-iodine-containing therapies for treatment of adenoviral conjunctivitis: A systematic review and network meta-analysis","volume":"101","author":"Chen","year":"2023","journal-title":"Acta Ophthalmol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/aos.13416","article-title":"Treatment of adenoviral keratoconjunctivitis with a combination of povidone-iodine 1.0% and dexamethasone 0.1% drops: A clinical prospective controlled randomized study","volume":"95","author":"Kovalyuk","year":"2017","journal-title":"Acta Ophthalmol."},{"key":"ref_41","first-page":"146864","article-title":"Biofunctionalization of nanoceria with sperminated hyaluronan enhances drug delivery performance for corneal alkali burn therapy","volume":"476","author":"Ger","year":"2023","journal-title":"CEJ"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1097\/ICO.0000000000001982","article-title":"Use of Topical Steroids in Conjunctivitis: A Review of the Evidence","volume":"38","author":"Holland","year":"2019","journal-title":"Cornea"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1136\/bjo.2010.188623","article-title":"A randomised placebo-controlled trial of topical steroid in presumed viral conjunctivitis","volume":"95","author":"Wilkins","year":"2011","journal-title":"Br. J. Ophthalmol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e201901206","DOI":"10.1590\/s0102-865020190120000006","article-title":"Comparative study on the efficacy of non-steroidal, steroid and non-use of anti-inflammatory in the treatment of acute epidemic conjunctivitis","volume":"34","author":"Santiago","year":"2020","journal-title":"Acta Cir. Bras."},{"key":"ref_45","first-page":"649","article-title":"Symptomatic Treatment of Subepithelial Infiltrates after Viral Conjunctivitis: Loteprednol or Dexamethasone?","volume":"25","author":"Sukgen","year":"2017","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1097\/ICO.0000000000002589","article-title":"Corticosteroids Versus Cyclosporine for Subepithelial Infiltrates Secondary to Epidemic Keratoconjunctivitis: A Prospective Randomized Double-Blind Study","volume":"40","author":"Gouider","year":"2021","journal-title":"Cornea"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s10384-020-00788-3","article-title":"Comparative study of topical regimen for adenoviral kearoconjunctivitis by 0.1% fluorometholone with and without polyvinyl alcohol iodine","volume":"65","author":"Matsuura","year":"2021","journal-title":"Jpn. J. Ophthalmol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"594","DOI":"10.4103\/ijo.IJO_1352_18","article-title":"Comparison of the safety and efficacy of topical Tacrolimus (0.03%) versus dexamethasone (0.05%) for subepithelial infiltrates after adenoviral conjunctivitis","volume":"67","author":"Bhargava","year":"2019","journal-title":"Indian. J. Ophthalmol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1097\/ICO.0b013e3181c33034","article-title":"Topical treatment with 1% cyclosporine for subepithelial infiltrates secondary to adenoviral keratoconjunctivitis","volume":"29","author":"Levinger","year":"2010","journal-title":"Cornea"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Okumus, S., Coskun, E., Tatar, M.G., Kaydu, E., Yayuspayi, R., Comez, A., Erbagci, I., and Gurler, B. (2012). Cyclosporine a 0.05% eye drops for the treatment of subepithelial infiltrates after epidemic keratoconjunctivitis. BMC Ophthalmol., 12.","DOI":"10.1186\/1471-2415-12-42"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1097\/ICO.0000000000000247","article-title":"Tacrolimus for the treatment of subepithelial infiltrates resistant to topical steroids after adenoviral keratoconjunctivitis","volume":"33","author":"Ghanem","year":"2014","journal-title":"Cornea"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"331","DOI":"10.2165\/11585330-000000000-00000","article-title":"Treatment of viral conjunctivitis with antiviral drugs","volume":"71","author":"Skevaki","year":"2011","journal-title":"Drugs"},{"key":"ref_53","first-page":"1812","article-title":"The antiviral resistance and replication of cidofovir-resistant adenovirus variants in the New Zealand White rabbit ocular model","volume":"42","author":"Romanowski","year":"2001","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1001\/archopht.119.10.1487","article-title":"Topical treatment of acute adenoviral keratoconjunctivitis with 0.2% cidofovir and 1% cyclosporine: A controlled clinical pilot study","volume":"119","author":"Hillenkamp","year":"2001","journal-title":"Arch. Ophthalmol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1089\/jir.1980.1.95","article-title":"Use of human fibroblast-derived (beta) interferon in the treatment of epidemic adenovirus keratoconjunctivitis","volume":"1","author":"Romano","year":"1980","journal-title":"J. Interferon Res."},{"key":"ref_56","first-page":"43","article-title":"Ten years of experience with human fibroblast interferon in treatment of viral ophthalmic infections","volume":"11","author":"Romano","year":"1988","journal-title":"Metab. Pediatr. Syst. Ophthalmol."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Romanowski, E.G., Yates, K.A., Daniels, E.J., Strem, B.M., Romanowski, J.E., and Kowalski, R.P. (2022). Ranpirnase (OKG-0301), a Novel Ribonuclease, Demonstrates Antiviral Activity against Adenovirus in the Ad5\/NZW Rabbit Ocular Replication Model. Pathogens, 11.","DOI":"10.3390\/pathogens11121485"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Urmi, U.L., Vijay, A.K., Willcox, M.D.P., Attard, S., Enninful, G., Kumar, N., Islam, S., and Kuppusamy, R. (2024). Exploring the Efficacy of Peptides and Mimics against Influenza A Virus, Adenovirus, and Murine Norovirus. Int. J. Mol. Sci., 25, Available online: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11240954\/.","DOI":"10.3390\/ijms25137030"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Lappin, M., Wotman, K., Chow, L., Williams, M., Hawley, J., and Dow, S. (2023). Nanoparticle ocular immunotherapy for herpesvirus surface eye infections evaluated in cat infection model. PLoS ONE, 18.","DOI":"10.1371\/journal.pone.0279462"}],"container-title":["Microorganisms"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-2607\/13\/8\/1712\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:13:48Z","timestamp":1760033628000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-2607\/13\/8\/1712"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,22]]},"references-count":59,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["microorganisms13081712"],"URL":"https:\/\/doi.org\/10.3390\/microorganisms13081712","relation":{},"ISSN":["2076-2607"],"issn-type":[{"value":"2076-2607","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,22]]}}}